NEW YORK (GenomeWeb) – BioLegend has licensed a multidimensional single-cell analysis technology from the New York Genome Center and is collaborating with the center on further research, the two organizations said today.
Under the agreement, BioLegend has obtained an exclusive worldwide license to CITE-seq, which stands for cellular indexing of transcriptomes and epitopes by sequencing, for research use. CITE-seq was developed by a team led by Marlon Stoeckius in NYGC's Technology Innovation Lab and published last year in Nature Methods.
CITE-seq enables researchers to simultaneously measure protein and RNA expression at the single-cell level. The technology complements BioLegend's portfolio of antibodies and biomedical reagents, allowing the company to expand into the space of genomic and transcriptomic profiling.
BioLegend is currently providing customers with custom CITE-seq antibody conjugates and plans to offer CITE-seq catalog products in the future.
"The capacity of CITE-seq to more finely dissect cell populations has many potential applications in clinical research, and is a powerful tool in international efforts to create a human single cell atlas," said Tom Maniatis, NYGC’s scientific director and CEO, in a statement. "Our CITE-seq license agreement and accompanying collaborative research agreement with BioLegend are good examples of how sharing innovative genomic tools widely with the scientific community has the potential to advance translational genomic science and advance efforts to realize the goals of precision medicine.”